Abstract

Metformin is a first-line drug treatment for type Ⅱ diabetes. Recent studies have showed that metformin can upregulate CycG2, induce mitochondria-mediated accumulation of reactive oxygen species (ROS), and inhibit the activity of transforming growth factor-β (TGF-β). Metformin could protect metastasis of nondiabetic breast cancer, and may become a chemopreventive drug for breast cancer. This review aims to clarify the inhibitory mechanism of metformin on the breast cancer and the drug resistance of metformin according to basic and clinical study. Key words: Breast neoplasms; Metformin; Diabetes mellitus; Research

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call